Higher tumor volume at baseline and worse responses to chemotherapy after four cycles — measured with PET scans — can predict poorer overall and event-free survival among patients with peripheral  T-cell lymphoma (PTCL), according to researchers from Memorial Sloan Kettering Cancer Center in New York. {read more here}